

# Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

## murine TCR OTI-2A.pMIG II

RRID:Addgene\_52111

Type: Plasmid

---

### Proper Citation

RRID:Addgene\_52111

---

### Plasmid Information

**URL:** <http://www.addgene.org/52111>

**Proper Citation:** RRID:Addgene\_52111

**Insert Name:** T cell receptor alpha chain

**Organism:** Mus musculus

**Bacterial Resistance:** Ampicillin

**Defining Citation:** [PMID:17406263](#)

**Vector Backbone Description:** Backbone Marker:Dario Vignali, Addgene plasmid 52107; Vector Backbone:pMIG II; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

**Comments:** The cDNAs encoding the TCRa (lacking the stop codon) and TCRb chains were linked via a 2A peptide into a single open reading frame by recombinant PCR and cloned into a mouse stem cell virus (MSCV)-based retroviral vector containing an IRES-GFP cassette to facilitate the identification of marked cells. The 2A peptide remains attached to the TCRa carboxy terminus and can be used to verify the complete separation of the two chains. Inclusion of a Gly-Ser-Gly (GSG) spacer between TCRa and the 2A peptide ensures complete 'cleavage'. We have not seen any deleterious effects of the 2A peptide on the function of any proteins examined thus far.

**Plasmid Name:** murine TCR OTI-2A.pMIG II

**Record Creation Time:** 20220422T222306+0000

**Record Last Update:** 20260725T074818+0000

---

### Ratings and Alerts

No rating or validation information has been found for murine TCR OTI-2A.pMIG II.

No alerts have been found for murine TCR OTI-2A.pMIG II.

---

## Data and Source Information

**Source:** [Addgene](#)

---

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Abdullah L, et al. (2025) The endogenous antigen-specific CD8+ T cell repertoire is composed of unbiased and biased clonotypes with differential fate commitments. *Immunity*, 58(3), 601.

Kadyrzhanova G, et al. (2025) Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors. *Frontiers in immunology*, 16, 1484303.

Holling GA, et al. (2024) CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity. *Cellular & molecular immunology*, 21(3), 260.

Sun ND, et al. (2024) TBK1 and IKK $\gamma$  protect target cells from IFN $\gamma$ -mediated T cell killing via an inflammatory apoptotic mechanism. *bioRxiv : the preprint server for biology*.

Lucero OM, et al. (2023) Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(20), 4230.

Zhou X, et al. (2023) MHC class II regulation of CD8+ T cell tolerance and implications in autoimmunity and cancer immunotherapy. *Cell reports*, 42(11), 113452.

Miao T, et al. (2017) Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation. *The Journal of experimental medicine*, 214(6), 1787.

Ghosh A, et al. (2017) Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. *Nature medicine*, 23(2), 242.